schedule at a glance

Register to the newsletter:

 

 

 

Share Experience and Know-how…

…A Programme of pragmatic workshops and conferences to Meet Concrete concerns with regard to project development, funding and operation

As usual EuroBiO will faithfully play its go-between’s role and gather a wide range of business leaders, including senior executives of leading biotech companies, large and mid-size pharmaceutical companies, start-ups, investors, tech transfer officers, academics and industry experts.


Because of the 2009 economic context, young innovative biotech companies face issues with finding funds to start and develop their business. In order to understand the stakes, experts and entrepreneurs will discuss on emerging biocompanies issues.


With the seeking of innovation and the wish to develop business; both academia and industry need to work on collaborative approaches. Indeed, collaborative deals might be an answer for both emerging companies looking for funding sources and matures companies looking for new research models. EuroBiO will present keynote speakers from transfer technology offices, academies and industries who will acquaint their experiences on technology transfer, collaborative research and public-private interaction.

 

Taking this context into account, EuroBiO will propose conferences like tool cases from which you can find useful answers and means. Over 110 keynote speakers will share their experiences on four relevant tracks for today’s and tomorrow’s Biotechs:

 

 

CONFERENCES PROGRAM



Thursday September 24 th, 2009




All the actors of the biotech sector are aiming to intensify academia/ industry partnerships, this vision being shared by all those belonging to the biotech community, mainly for the following reasons:
  • Conducting effective therapeutic and diagnostic innovative projects requires competences that must come from both public research and private research
  • It has become less and less possible to succeed in biotech research alone, as a young company or as a major firm
This situation has led many governments and public agencies to create new funding schemes to foster industry/academia collaboration. Given the increasing number of collaborative programmes, licensing and technology transfer issues must be taken into account. This track will cover several topics that will be presented by a panel of speakers from the whole of the biotech community (Office of Technology Transfer, mature companies, start-ups) and highlight innovative ways to organize new collaborations.
 

09:30 - 11:00 Clearly defining scientific and technological background before signing a collaborative deal.


The latest innovations are stemming increasingly from joint development between corporations on the one side and corporations/universities on the other side. One of the toughest issues we face is how to define the scientific and technological background of the two parties to a program. Since this contribution has strong repercussions on the ownership of the intellectual property and the distribution of financial returns, this needs to be clarify as quickly as possible. It is also in the early stage of discussions that it is important to approach the subject of freedom of operation.

Chairman
Dave Tapolczay | MRC-T - CEO
DOWNLOAD THE PRESENTATION

Speakers
Michel Azoulay | Gold Islands Consulting - CEO
Anthony Baxter | Cyprotex - CEO
DOWNLOAD THE PRESENTATION

Manfred Horst | Merck Sharp & Dohme France - Director Licensing & External Research Europe
DOWNLOAD THE PRESENTATION





11:30 - 12:30 Plenary session


Speakers
Martine Aubry | Lille City - Mayor
Jean-Claude Muller | Sanofi-aventis - Senior Vice President Prospective and Strategic Initiatives
Philippe Pouletty | France Biotech - Honorary President
Fred Reinhart | Association of University Technology Managers - Vice President




14:00 - 16:00 Academia/ industry partnerships in drug discovery: the latest news on the IMI initiative


The Innovative Medicine Initiative aims to speed up drug discovery and development and hence to foster Europe’s competitiveness in the pharmaceutical sector. With a first call launched last year, what feedback has there been on this initiative? What scientific direction has been illustrated by the projects submitted? What is the respective involvement of SMEs and large pharmaceutical companies in the consortia as per the calls selected? What direction is expected of the IMI in the forthcoming years? Our panel of experts will provide a comprehensive view of the IMI, indicating the first steps taken, and comment on the suitability of IMI for biotech start-ups.

Chairman
Patrick Tricoli | Sanofi-Aventis - R&D, External Innovation Department, Access to Innovation Europe Head
Speakers
Jacqueline Hunter | GlaxoSmithKline - SVP Science Environment Development
DOWNLOAD THE PRESENTATION

Irene Norstedt | European Commission - Head of Sector IMI
DOWNLOAD THE PRESENTATION

Xavier Regnaut | Innovative Health Diagnostics - CEO
DOWNLOAD THE PRESENTATION

Bernard Thorens | Lausanne University - Professor
DOWNLOAD THE PRESENTATION





16:30 - 18:30 Transfer of technology: the specificities of a know-how out-licensing process


The licensing of know-how requires taking a look on the specific features involved. When is the right time to license one’s know-how? How can the right partner be identified? What are the ways to manage an effective out-licensing process, particularly in the case of spin-offs? This session will an opportunity to exchange good practices and share ideas by taking a look at examples as well as at experiences abroad.

Chairman
Conny Bogentoft | Karolinska Development - CEO
DOWNLOAD THE PRESENTATION

Speakers
Désiré Collen | ThromboGenics NV – Founder and Chairman
DOWNLOAD THE PRESENTATION

Ora Horovitz | BGN Technologies - VP Business Development
DOWNLOAD THE PRESENTATION

Sam Ogunsalu | Queen Mary Innovation Ltd.- Principal Executive Commercial Development
DOWNLOAD THE PRESENTATION

Bruno Pagliara | on-kòs Pharma Milano - CEO
DOWNLOAD THE PRESENTATION

Carina Schmidt | Athera Biotechnologies AB - CEO
DOWNLOAD THE PRESENTATION








One of the few things we can be certain of is that the year 2009 will be one of uncertainties. The reduction in availability of VC and seed money in 2009 shows practically no doubt. In such a context, emerging and young biotech companies must make critical decisions to optimize their expenses, rethink options as whether to perform internally or outsource part of their expertises and give new thought to defining their core projects and priorities. This difficult year did however open up opportunities. Public funding schemes budgets will most probably remain stable, and thus offer solutions in terms of cash flow. The public policies that target innovation will be increasingly more directed toward public-private partnerships. It also appears to be ever more likely that the breakdown between equity and loans will change durably. All this is creating a need for emerging companies to re-engineer their business model and obtain cash services and partnership deals rather than being backed totally by equity.

 


09:30 - 11:00 Establish win-win models with your service suppliers: outsourcing deals


To be competitive, outsourcing parts of its projects is now a necessary path for a biotech company. Saving costs or increasing R&D productivity, what needs are to be considered in terms of outsourcing? It is essential to determine which competence should be present within a company. Then, how to manage a successful relationship with your subcontractors? Can you implement interesting deals with outsourcing? This workshop will raise questions as what needs to remain inside the company and how to manage outsourcing.

Chairman
Richard Dennett | Eden BioDesign - Head of Consultancy Services
DOWNLOAD THE PRESENTATION

Speakers
Kevin Bilyard | Nine-TZ Healthcare Venture - Principal & Co-Owner
DOWNLOAD THE PRESENTATION

Jean-François Bloch | Proteus - Deputy General Manager
DOWNLOAD THE PRESENTATION

Gilles Devillers | Pages Partners - Pharm-D MBA
DOWNLOAD THE PRESENTATION

Yasmin Karimi-Nejad | Solvay Pharmaceuticals GmbH - Research Scout Technology




11:30 - 12:30 Plenary session


Speakers
Martine Aubry | Lille City - Mayor
Jean-Claude Muller | Sanofi-aventis - Senior Vice President Prospective and Strategic Initiatives
Philippe Pouletty | France Biotech - Honorary President
Fred Reinhart | Association of University Technology Managers - Vice President




14:00 - 16:00 Seed investors: how far upstream do these specialized early stage financing tools go in this harsh 2009 context?


Since several months it has become harder for VCs to raise money. The availability of VC and seed cash will decrease considerably in the forthcoming quarters. On which criteria will seed and VC investors base their choices with regard to investing in new companies? Different examples and testimonies from recently-launched companies and investors will open up opportunities for understanding the new expectations of the financial community regarding the maturation level of newcomers.

Chairman
Jean-Yves Nothias | SGAM - Managing Director Biotechnology Investments
Speakers
Simone Botti | Rad Biomed - Director of Business Development
DOWNLOAD THE PRESENTATION

Magnus Corfitzen | Sunstone Capital, Life Science Ventures - Investment Director
Jim Phillips | Vantia Therapeutics - CEO
DOWNLOAD THE PRESENTATION

Dave Smardon | Bioenterprise Corporation - President and Director
DOWNLOAD THE PRESENTATION





16:30 - 18:30 The Era-net funding scheme: the best tool adapted to encourage SME collaboration in transnational research projects?


The Era-net European programmes (EuroTransBio, Erasysbio, Neuron etc.) hope to promote transnational research and thus to reinforce the competitiveness of European biotechnology industry. Which projects have been successful to small biocompanies? What are the impressions of companies having taken part in these programmes? In this session, our panel expert will provide a comprehensive view of the biotech Era-net programme as well as its impact on the biotech industry. the panel will also try and see the perspectives of evolution of such programmes. Once again, testimonies and experiences of young biocompanies will give an inside look to the previously-raised questions.

Chairman
Stephane Hogan | European Commission - Head of Coordination Unit, Directorate Health, DG Research
Speakers
Jean-Baptiste Dumas | Helios Bioscience - Director
DOWNLOAD THE PRESENTATION

Matilde Fernandez | Bio-Lliberis Research &Development - Head of I+D Department
DOWNLOAD THE PRESENTATION

Pierre Noel Lirsac | CEA - Deputy Director Technology for Health
DOWNLOAD THE PRESENTATION

Hans Van Der Saag | BioActor - Managing Director
DOWNLOAD THE PRESENTATION








Young companies as well as large pharmaceutical groups and the whole of the biotech industry are faced with many regulatory challenges and an increasingly regulated framework. These regulations are constantly evolving. Therefore, biotech companies need to adapt to the changes brought on by new legislation. Either at seminars or round-table discussions, this track will present updated information on major political and regulatory affairs that shape the biotechnology industry such as biosimilar products or issues linked to gene and cell therapies. Through diverse sessions, it will take stock of the new regulations, market opportunities and show how they affect biotech companies.
 

09:30 - 11:00 Regulatory requirements on production of Monoclonal Antibodies


Due to their specificity, Monoclonal Antibodies have complex manufacturing processes. Small changes in these processes might induce considerable consequences on the product, the clinical safety and/or efficacity. Then, what are the current regulatory requirements and guidance with respect to Monoclonal Antibodies? What are the necessary skills, experience and technology to develop the manufacturing processes and produce MAbs?

Chairman
Christian Béchon | LFB - CEO
DOWNLOAD THE PRESENTATION

Speakers
Philippe Baumgartner | Avecia Biotechnology - Associate Director of Early Phase Development
DOWNLOAD THE PRESENTATION

Christian Béchon | LFB - CEO
DOWNLOAD THE PRESENTATION

Yann Echelard | GTC Biotherapuetics - VP of Research and Development
DOWNLOAD THE PRESENTATION





11:30 - 12:30 Plenary session


Speakers
Martine Aubry | Lille City - Mayor
Jean-Claude Muller | Sanofi-aventis - Senior Vice President Prospective and Strategic Initiatives
Philippe Pouletty | France Biotech - Honorary President
Fred Reinhart | Association of University Technology Managers - Vice President




14:00 - 16:00 Regulation of biomarkers used in personalised medicine


Many effective biomarkers are already being used in treatment monitoring and drug development. Now the research community tries and develops diagnostics and treatments tools from more complex molecular biomarkers. Indeed, the integration of biomarker in clinical programmes might foster the development of new medical products and promote personalised medicine. However, it is essential to establish the clinical pertinence of such biomarkers. What are the current systems of validation of new biomarker discovery? How regulation policies accelerate development of biomarker?

Chairman
Emmanuel Chantelot | European Biopharmaceutical Enterprises - Executive Director
Speakers
Bruno Flamion | University of Namur - Full Professor, Head of the Laboratory of Physiology and Pharmacology
DOWNLOAD THE PRESENTATION

William Gallagher | OncoMark Limited - CEO/CSO
Maria Isaac | EMEA - Member of the Scientific Advice team
Thomas Metcalfe | F. Hoffmann-La Roche - Global Head Personalised Healthcare Portfolio
DOWNLOAD THE PRESENTATION





16:30 - 18:30 Opportunities and challenges for biosimilar products in the global market


With a large number of products patent soon to expire, what opportunities lie ahead for biosimilar products? And what role do such products play today on the market? Do they fill in an existing gap, do they create a new market or do they compete with existing drugs?  But before accessing this highly attractive market, biotech companies first need to jump over many barriers: new regulatory framework in the EU, investment linked to biosimilar products development, cost incurred by manufacturers etc. In this seminar, our panel of experts will analyze how biocompanies can jump over hurdles in order to exploit the potential of biosimilar products.


Chairman
Robert Blakie | ERA Consulting - Director of Regulatory Affairs and General Manager (UK)
Speakers
Robert Blakie | ERA Consulting - Director of Regulatory Affairs and General Manager (UK)
Michel de Baar | OctoPlus - Senior Manager Business Development
DOWNLOAD THE PRESENTATION

William Haddad | Biogenerics, Inc. - Chairman&CEO
Kowid Ho | AFSSAPS - Biologicals/Biotechnology Unit
DOWNLOAD THE PRESENTATION






Friday September 25 th, 2009




All the actors of the biotech sector are aiming to intensify academia/ industry partnerships, this vision being shared by all those belonging to the biotech community, mainly for the following reasons:
  • Conducting effective therapeutic and diagnostic innovative projects requires competences that must come from both public research and private research
  • It has become less and less possible to succeed in biotech research alone, as a young company or as a major firm
This situation has led many governments and public agencies to create new funding schemes to foster industry/academia collaboration. Given the increasing number of collaborative programmes, licensing and technology transfer issues must be taken into account. This track will cover several topics that will be presented by a panel of speakers from the whole of the biotech community (Office of Technology Transfer, mature companies, start-ups) and highlight innovative ways to organize new collaborations.
 

09:30 - 11:00 Objective look at research valorisation options


Too often the choice between creating a spin-off company and out-licensing a technology to a company is guided by non-objective criteria. Some experts will say that they decided to create a spin-off, as they had identified some entrepreneurial skills in the academic reserach group from which the IP or technology is originally. Others will consider spin-off option only when they find no existing company interested in the technology. And others TTOs will market their technology in the seed and VC community and choose their option following the marketing process of their technology. How do most advanced universities cope with that question of choosing between licensing to a pre-existing company or creating a spin-off? This workshop will be above all presented by technology transfer experts from universities.

Chairman
Brian Kelly | Cornell Center for Technology Enterprise and Commercialization – Director
Speakers
Rudy Dekeyser | VIB Technology Transfer - Manager
DOWNLOAD THE PRESENTATION

Heung-Chae Jung | Korea Research Institute of Bioscience and Biotechnology - Director of Intellectual Property Management Department
DOWNLOAD THE PRESENTATION

Axel Koch | ElexoPharm GmbH - CEO
DOWNLOAD THE PRESENTATION





11:30 - 13:00 Academic platforms vs. technology-based services companies: Competitors or Partners?


Do the schemes devoted to increase the use of big public platforms hinder or encourage the appearence of technology-based services companies with respect to the competition? Given the different economic models, is competition fair? In this round-table, different technology-based services companies will speak of either their fruitful collaborations or their difficulties in competing with such entities.

Chairman
Douwe Breimer | Leiden University - Professor of Pharmacology
DOWNLOAD THE PRESENTATION

Speakers
François Bocquel | Phenopro - Head of Operations and Business Corporate
DOWNLOAD THE PRESENTATION

Thomas Hankemeier | Netherlands Metabolomics Consortium - Scientific Director
Max van Min | FlexGen - Marketing & Sales Manager
DOWNLOAD THE PRESENTATION





14:00 - 16:00 How to choose the right licensing strategy?


Every licensing agreement is unique. Indeed, the deal has to take into account the needs and expectations of the two parties, the intellectual property rights, upfront, milestones and royalties payments. Then according to the technology licensed and the typology of the licensor structure, what is the right strategy for licensing? Our panel experts will make a critical analysis on the choice of the licensing strategy.

Chairman
Amir Naiberg | Yeda - CEO
DOWNLOAD THE PRESENTATION

Speakers
Jean-Bernard Borfiga | Les Laboratoires Servier - Head of Scientific Collaboration & Business Development
DOWNLOAD THE PRESENTATION

Garold Breit | Manitoba University TTO - Executive Director
DOWNLOAD THE PRESENTATION

Rouget Henschel | Foley & Lardner - Partner
Bjoern Colin Kahrs | Merck Sereno - Patent Manager
Noam Shani | Kahr Medical - CEO
DOWNLOAD THE PRESENTATION








One of the few things we can be certain of is that the year 2009 will be one of uncertainties. The reduction in availability of VC and seed money in 2009 shows practically no doubt. In such a context, emerging and young biotech companies must make critical decisions to optimize their expenses, rethink options as whether to perform internally or outsource part of their expertises and give new thought to defining their core projects and priorities. This difficult year did however open up opportunities. Public funding schemes budgets will most probably remain stable, and thus offer solutions in terms of cash flow. The public policies that target innovation will be increasingly more directed toward public-private partnerships. It also appears to be ever more likely that the breakdown between equity and loans will change durably. All this is creating a need for emerging companies to re-engineer their business model and obtain cash services and partnership deals rather than being backed totally by equity.

 


09:30 - 11:00 Public funding policies: which options for small innovative companies in 2009?


Raising money for almost any new technology is not easy. Nevertheless, there are many European funding options for small innovative companies, e.g. European Framework Program, Eurostars, Eureka. All of them show ways for biocompanies to develop their research activities with European added value. How is it possible to know which programme to apply? Which programme is the most adapted to your company? This session will give a comprehensive view of the different public funds. By sharing their experiences, young companies will reveal how these programs have influenced their development, help them to identify the right partners and become a part of a network.

Chairman
Luuk Borg | Secretariat Eureka - Head
Speakers
Annabelle Ascher | European Commission - Scientific Officer and Policy Developer
DOWNLOAD THE PRESENTATION

Dirk Carrez | EuropaBio - Director Industrial Biotechnology
DOWNLOAD THE PRESENTATION

Christophe Olivier | InnoBioChips - R&D project manager
DOWNLOAD THE PRESENTATION

Remy Renaudin | Eureka - French National Project Coordinator
DOWNLOAD THE PRESENTATION





11:30 - 13:00 CRO/ Biotech: building win-win relationships


Looking at relationships between CROs and biotech companies, the conclusion is that incomprehension stands between the two parties due to different expectations and needs. Finance, strategy, requirement... what are the real conflict points? Then, how to reach a trade-off? Without taboo, both sides will state their position and requirement. In this round-table, CROs and biocompanies will analyse what it takes to build productive and efficient relationships.

Moderator
Anne Lise Berthier | BioPharmaceutiques - Chief Redactor
Speakers
Enrico Bastianelli | Bone Therapeutics - CEO
Jeannie Brooks | BioMimetic Therapeutics - Associate Director, Clinical Affairs
Antoine Cournot | Eucrof - President
Edgar Fenzl | FGK Clinical Research - Managing Director, Founder and Principal
Göran Forsberg | Active Biotech AB - VP Investor Relations & Business Development
Daniel Spasic | TFS - CEO
Adam Svobodnik | ADDS - Country Manager
Oliver Wiedemann | EpiCept GmbH - Director of Medical Affairs




14:00 - 16:00 Portfolio management and risk assessment


In the early stages, and with limited resources, a small company often focuses on a single application of its service or technology. However, entrepreneurs do often realize that their technology has other fields of application than their first purpose. Then how to identify, select and manage a new project from R&D? What is the impact of resources allocation to new projects on the company's management? Through testimonies, this session will present young companies that have successfully increased their portfolio. Find out how these companies took on such a challenge.

Chairman
Roger Holdsworth | UCB - Head, R&D Portfolio Management
DOWNLOAD THE PRESENTATION

Speakers
Kerstin Bode-Greuel | Bioscience Valuation - Founder and Managing Partner
DOWNLOAD THE PRESENTATION

Mellor Hennessy | AstraZeneca - Global Portfolio Strategist
Andre Hoekema | Galapagos - SVP Corporate Development
DOWNLOAD THE PRESENTATION

Klaus Nickisch | Evestra - CSO
DOWNLOAD THE PRESENTATION








Young companies as well as large pharmaceutical groups and the whole of the biotech industry are faced with many regulatory challenges and an increasingly regulated framework. These regulations are constantly evolving. Therefore, biotech companies need to adapt to the changes brought on by new legislation. Either at seminars or round-table discussions, this track will present updated information on major political and regulatory affairs that shape the biotechnology industry such as biosimilar products or issues linked to gene and cell therapies. Through diverse sessions, it will take stock of the new regulations, market opportunities and show how they affect biotech companies.
 

09:30 - 11:00 Environmental biotechnology regulation: vector for creation of new markets?


Bioproducts might have health and environmental side-effects. in order to reach our ambition in terms of environment and sustainable development, biocompanies need to explore new fields. Therfore, public authorities need to provide a stable framework for business to grow and invest. How can the regulation be a factor of new market creation in Europe? What elements will push the biotech companies into investing in new innovative domains? In this session, our experts will take a comprehensive look at the European environmental biotechnology industry, on the regulation as wll as on application market opportunities.

Chairman
Ulrich Stottmeister | International Society of Environmental Biotechnology – Board Member
DOWNLOAD THE PRESENTATION

Speakers
Willy de Greef | Europabio - Secretary General
DOWNLOAD THE PRESENTATION

Piet Lens | EFB - Chairman, Section on Environmental Biotechnology
Ulrich Stottmeister | International Society of Environmental Biotechnology – Board Member
DOWNLOAD THE PRESENTATION





11:30 - 13:00 The booming in synthetic biology: what does the future hold?


Synthetic biology is an emerging field of biology but one of the most dynamic. Indeed, this area holds a great promise for the development of low-cost drugs, production of biomaterials or sustainable chemicals by biotransformation. Synthetic biology aims to provide bio-based technologies and tools quickly marketable for industries, and thus achieve early return on investment. This field should become attractive for any innovative life science industry. What is the European strategy regarding synthetic biology? What are the perspectives and opportunities in Europe? How will national and international policies form guidance and regulation regarding risk assessment, prevention of misuse and other synthetic biology issues?

Chairman
Sibylle Gaisser | Fraunhofer Institute Systems and Innovation Research – Coordinator Tessy project
DOWNLOAD THE PRESENTATION

Speakers
François Képès | Genopole – CNRS Research Director
DOWNLOAD THE PRESENTATION

Philippe Marlière | Global Bioenergies - Co-founder
Markus Schmidt | Organisation for International Dialogue and Conflict Management - Coordinator Synbiosafe project
DOWNLOAD THE PRESENTATION





14:00 - 16:00 Technical and regulatory obstacles for stem cell therapies


Many advances have been made in stem cell therapies, while major obstacles need to be overcome in order to develop therapies for patients. Moreover, there is a huge gap between the advances made in Europe, America and Asia. This seminar will shed light on the current regulatory landscape for conducting clinical research on stem cells and regenerative medicine. How will regulations evolve and how will the regenerative medicine industry continue to develop?

Chairman
Chris Mason | University College London - Professor
Speakers
Mikael Englund | Cellartis AB - Senior Scientist
DOWNLOAD THE PRESENTATION

Paul Kemp | Intercytex - CSO and Executive Director
DOWNLOAD THE PRESENTATION

Susanna Narkilahti | The Regea Institute for Regenerative Medicine - Senior Researcher
Philip Vanek | Lonza Bioscience - Cell Therapy, Head of Business Development
DOWNLOAD THE PRESENTATION








The aim of this track is to emphasize the fruitful and pragmatic inter-cluster partnerships and stress the impact these partnerships have in terms of therapeutic or enabling innovations, in terms of creation of ambitious collaborative programmes carried out by the clusters’ respective members or in terms of useful innovative tools these clusters propose to their members. This track will focus on innovations and achievements stemming from European bioclusters. Different research areas (cancer, immunotherapy, bioproduction, pharmaceutical chemistry…) will be dealt with by scientists and CSOs originating from different clusters.
Through testimonials, the different members of clusters will speak about their successes and emblematic projects. In this track, and through those different illustrations, the aim is to show the importance of cluster’s management and teams in the construction of a knowledge-based bioeconomy in Europe. Our choice in this track is to be able to hear what entities benefiting from the cluster process say i.e. SMEs, academic researchers taking part in the life of their respective cluster.

 


09:30 - 11:00 Innovative radiopharmaceuticals: a realistic application of personalized medicine by Atlantic Biotherapies.


In order to foster the development of targeted radiotherapy, the community of the Atlantic Biotherapies cluster get organized around a core facility (a unique Cyclotron of 35M€) , technological convergences (from oncology to radiochemistry and nulcear physics), start-ups and innovative SMEs.
Thanks to a practical structuring methodology, this community has raised substantial R&D collaborative projects (2 projects of 30M€) which involve major European industries and lead to the establishment of innovative companies.
Arronax and the radiopharmaceutical sciences show how consistent funds can leverage private R&D investments in a cluster priority field.

Chairman
Jean-François Chatal | Arronax - Scientific Advisor
DOWNLOAD THE PRESENTATION

Speakers
Réjane Bihan | Atlantic Biotherapies - Biotechnology Projects Manager
Jean-Marc Le Doussal | Atlab Pharma - co-founder and President
Anthony Loussouarn | Chelatec -CEO
Maurizio Franco Mariani | 3A - Head of Research and Development
Richard Zimmerman | IBA - Vice President Radiopharmaceutical Development




11:30 - 13:00 Research facilities: innovative models for public-private partnerships


The session will address the role of clusters in developing partnerships between academia and the private sector in various areas, while focussing on technology platforms and research infrastructures. Illustrations will be provided through few projects and key succes factors will be highlighted.

Chairman
Nicolas Carboni | Alsace Biovalley - General Manager
Speakers
Daniel Denis | Secor - Senior Partner
DOWNLOAD THE PRESENTATION

Bertrand Loubaton | GE Healthcare - Director, Pharmaceutical & Academic Collaboration
Robert Sarisky | Johnson & Johnson Pharmaceuticals, LLC - Vice President, External Research & Early Development
DOWNLOAD THE PRESENTATION





14:00 - 15:30 From national projects to European research programmes


Globalisation of research and innovation and global competition are putting a new emphasis on the role of regional clusters and further their development. Clusters increasingly see the need to link with other clusters on the international level.
In Europe, regional clusters seen as key drivers for competitiveness, innovation and regional development are being promoted through both national-level measures, particularly in France with the support of the FUI and EU-level support instruments, notably the 7th EU Research Framework Programme.
The clusters contribute also to the internationalization of projects that were previously launched at a regional/national level for the reinforcement of the international competitiveness and to accelerate their development.

Chairman
Alain Yvorra | Eurobiomed - Managing Director
Speakers
Binah Baum | Bio Negev cluster - founder
DOWNLOAD THE PRESENTATION

Frédéric Druck | BioWin - Director, Communication & International Relations
DOWNLOAD THE PRESENTATION

Gérard Papierok | BIO VETO TEST – Scientific Manager






© EuroBio 2009 | Credits | edikka
Co-organisers: |